85 related articles for article (PubMed ID: 38667336)
21. Treatment-Free Remission-A New Aim in the Treatment of Chronic Myeloid Leukemia.
Kwaśnik P; Giannopoulos K
J Pers Med; 2021 Jul; 11(8):. PubMed ID: 34442340
[TBL] [Abstract][Full Text] [Related]
22. Assessment of droplet digital polymerase chain reaction for measuring BCR-ABL1 in chronic myeloid leukaemia in an international interlaboratory study.
Scott S; Cartwright A; Francis S; Whitby L; Sanzone AP; Mulder A; Galimberti S; Dulucq S; Mauté C; Lauricella C; Salmon M; Rose S; Willoughby J; Boeckx N; Pallisgaard N; Maier J; Leibundgut EO; Zizkova H; Ling Goh L; Duong C; Tang WF; Ma E; Shivakumar Y; Beppu L; Bhagavatula P; Chantry A
Br J Haematol; 2021 Jul; 194(1):53-60. PubMed ID: 34114218
[TBL] [Abstract][Full Text] [Related]
23. Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape.
Hsieh YC; Kirschner K; Copland M
Leukemia; 2021 May; 35(5):1229-1242. PubMed ID: 33833387
[TBL] [Abstract][Full Text] [Related]
24. Treatment-free remission and immunity in chronic myeloid leukemia.
Ureshino H
Int J Hematol; 2021 May; 113(5):642-647. PubMed ID: 33651270
[TBL] [Abstract][Full Text] [Related]
25. Influence of major
Genthon A; Nicolini FE; Huguet F; Colin-Gil C; Berger M; Saugues S; Janel A; Hayette S; Cohny-Makhoul P; Cadoux N; Cayuela JM; Campos L; Guyotat D; Flandrin-Gresta P
Oncotarget; 2020 Jun; 11(26):2560-2570. PubMed ID: 32655840
[TBL] [Abstract][Full Text] [Related]
26. Withdrawal Syndrome After Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia in the Russian Prospective Study RU-SKI.
Petrova A; Chelysheva E; Shukhov O; Bykova A; Nemchenko I; Gusarova G; Tsyba N; Julhakyan H; Shuvaev V; Fominykh M; Martynkevich I; Ionova T; Turkina A
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):267-271. PubMed ID: 32146103
[TBL] [Abstract][Full Text] [Related]
27. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
Hochhaus A; Baccarani M; Silver RT; Schiffer C; Apperley JF; Cervantes F; Clark RE; Cortes JE; Deininger MW; Guilhot F; Hjorth-Hansen H; Hughes TP; Janssen JJWM; Kantarjian HM; Kim DW; Larson RA; Lipton JH; Mahon FX; Mayer J; Nicolini F; Niederwieser D; Pane F; Radich JP; Rea D; Richter J; Rosti G; Rousselot P; Saglio G; Saußele S; Soverini S; Steegmann JL; Turkina A; Zaritskey A; Hehlmann R
Leukemia; 2020 Apr; 34(4):966-984. PubMed ID: 32127639
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia.
Franke GN; Maier J; Wildenberger K; Cross M; Giles FJ; Müller MC; Hochhaus A; Niederwieser D; Lange T
J Mol Diagn; 2020 Jan; 22(1):81-89. PubMed ID: 31669230
[TBL] [Abstract][Full Text] [Related]
29. Epidemiologic Signatures in Cancer.
Welch HG; Kramer BS; Black WC
N Engl J Med; 2019 Oct; 381(14):1378-1386. PubMed ID: 31577882
[No Abstract] [Full Text] [Related]
30. Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type.
Baccarani M; Rosti G; Soverini S
Leukemia; 2019 Oct; 33(10):2358-2364. PubMed ID: 31455852
[TBL] [Abstract][Full Text] [Related]
31. Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome.
Berger MG; Pereira B; Rousselot P; Cony-Makhoul P; Gardembas M; Legros L; Escoffre-Barbe M; Nicolini FE; Saugues S; Lambert C; Réa D; Guerci-Bresler A; Giraudier S; Guilhot J; Saussele S; Mahon FX;
Br J Haematol; 2019 Nov; 187(3):337-346. PubMed ID: 31271217
[TBL] [Abstract][Full Text] [Related]
32. Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay.
Kjaer L; Skov V; Andersen MT; Aggerholm A; Clair P; Gniot M; Soeby K; Udby L; Dorff MH; Hasselbalch H; Pallisgaard N
Eur J Haematol; 2019 Jul; 103(1):26-34. PubMed ID: 30985947
[TBL] [Abstract][Full Text] [Related]
33. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D
Cancer Med; 2019 May; 8(5):2041-2055. PubMed ID: 30950237
[TBL] [Abstract][Full Text] [Related]
34. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
35. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.
Hsu J; Hodgins JJ; Marathe M; Nicolai CJ; Bourgeois-Daigneault MC; Trevino TN; Azimi CS; Scheer AK; Randolph HE; Thompson TW; Zhang L; Iannello A; Mathur N; Jardine KE; Kirn GA; Bell JC; McBurney MW; Raulet DH; Ardolino M
J Clin Invest; 2018 Oct; 128(10):4654-4668. PubMed ID: 30198904
[TBL] [Abstract][Full Text] [Related]
36. Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML.
Brück O; Blom S; Dufva O; Turkki R; Chheda H; Ribeiro A; Kovanen P; Aittokallio T; Koskenvesa P; Kallioniemi O; Porkka K; Pellinen T; Mustjoki S
Leukemia; 2018 Jul; 32(7):1643-1656. PubMed ID: 29925907
[TBL] [Abstract][Full Text] [Related]
37. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib.
Breccia M; Molica M; Colafigli G; Massaro F; Quattrocchi L; Latagliata R; Mancini M; Diverio D; Guarini A; Alimena G; Foà R
Oncotarget; 2018 Jan; 9(7):7534-7540. PubMed ID: 29484130
[TBL] [Abstract][Full Text] [Related]
39. Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study.
Rea D; Henry G; Khaznadar Z; Etienne G; Guilhot F; Nicolini F; Guilhot J; Rousselot P; Huguet F; Legros L; Gardembas M; Dubruille V; Guerci-Bresler A; Charbonnier A; Maloisel F; Ianotto JC; Villemagne B; Mahon FX; Moins-Teisserenc H; Dulphy N; Toubert A
Haematologica; 2017 Aug; 102(8):1368-1377. PubMed ID: 28522576
[TBL] [Abstract][Full Text] [Related]
40. E14a2
Claudiani S; Apperley JF; Gale RP; Clark R; Szydlo R; Deplano S; Palanicawandar R; Khorashad J; Foroni L; Milojkovic D
Haematologica; 2017 Aug; 102(8):e297-e299. PubMed ID: 28495914
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
